Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program ; volume:34 ; number:3 ; day:29 ; month:1 ; year:2020 ; pages:299-310 ; date:3.2020
CNS drugs ; 34, Heft 3 (29.1.2020), 299-310, 3.2020
- Urheber
-
Doherty, Teodora
Wajs, Ewa
Melkote, Rama
Miller, Janice
Singh, Jaskaran B.
Weber, Michael A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-020-00699-4
- URN
-
urn:nbn:de:101:1-2020052300110773587179
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:04 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Doherty, Teodora
- Wajs, Ewa
- Melkote, Rama
- Miller, Janice
- Singh, Jaskaran B.
- Weber, Michael A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Personalized use of ketamine and esketamine for treatment-resistant depression
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Personalized use of ketamine and esketamine for treatment-resistant depression
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Personalized use of ketamine and esketamine for treatment-resistant depression
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report